key: cord-1050368-uorxkduf
authors: Hu, Zhi-min; Wang, Lan-lan; Zou, Liang; Chen, Zhong-ju; Yi, Yang; Meng, Qin-bin; Feng, Yan
title: Coinfection pulmonary mucormycosis and aspergillosis with disseminated mucormycosis involving gastrointestinalin in an acute B-lymphoblastic leukemia patient
date: 2021-07-03
journal: Braz J Microbiol
DOI: 10.1007/s42770-021-00554-8
sha: e567c1de545d8c6ec44aeb93d48b73bee4aa2a17
doc_id: 1050368
cord_uid: uorxkduf

Pulmonary mucormycosis and aspergillosis with disseminated mucormycosis involving gastrointestinalin is a very rare but lethal infection leading to extreme mortality. Herein, we present a unique case of pulmonary coinfection with Cunninghamella bertholletiae and Aspergillus flavus, with disseminated mucormycosis involving the jejunum caused by C. bertholletiae in an acute B-lymphocytic leukemia (B-ALL) patient with familial diabetes. Early administration of active antifungal agents at optimal doses and complete resection of all infected tissues led to improved therapeutic outcomes.

(B-ALL) with the IKZF1 mutation was diagnosed by bone marrow pathology. Considering her history of familial diabetes and percutaneous coronary intervention, the chemotherapy program was initiated with a low dose of vindesine sulfate and dexamethasone and oral prophylactic treatment with fluconazole simultaneously. Serologies for (1,3)-betad-glucan, galactomannan (GM) (Dynamiker Biotechnology Co., Ltd. Tianjin, China), syphilis, acquired immunodeficiency syndrome, and hepatitis A-E were negative. One month later, bone marrow pathology was repeated and showed 12% blast cells. A high-intensity IVCP program was performed. After 5 days, broad-spectrum antibiotics and voriconazole were started due to febrile neutropenia.

On day 49, significant pulmonary symptoms, such as productive cough, occurred, along with a persistent fever. Computed tomography (CT) showed a massive high-density shadow in the right superior lobe (Fig. 1) and rising levels of C-reactive protein (CRP). Blood culture was sterile, and polymerase chain reaction for cytomegalovirus and EB virus were negative. Anti-biotherapy was switched to meropenem and linezolid, but there was no obvious relief in symptoms. On day 51, the serum GM antigen test was positive (2.38), and the microbiological tests were implemented with bronchoalveolar lavage fluid (BALF). Classically, microscopic evaluation with Gram ( Fig. 2A) and calcofluor white (Fig. 2B ) staining revealed filamentous hyphae; one type was uniformly thinner, septate, and branching at acute angles, and the other had a variable width, was nonseptate, and had branching filamentous hyphae and a ribbon-like appearance. Cultures of specimens on Sabouraud Dextrose Colonies appeared cotton and white-gray, both on the surface and reverse side (Fig. 2C ). Lactophenol cotton blue staining revealed irregularly branching sporangiophores terminating prominently, and sporangioles borne off the vesicles (Fig. 2E) . Cunninghamella bertholletiae was identified by mycological characteristics and internal transcribed spacer (ITS)-based sequencing (accession no.MT470208). DNA sequences were analyzed using NCBI BLAST (https:// blast. ncbi. nlm. nih. gov/ Blast. cgi). Another pathogen isolated from BALF was Aspergillus flavus (accession no. MW911813).

Based on the characteristics of the filamentous hyphae, we switched the antifungal therapy to intravenous amphotericin B deoxycholate (d-AmB) with an initial dose of 0.5 mg/kg/day. Persistent fever was resolved, but unexpectedly, acute abdominal pain with high fever and a "sudden drop" in blood pressure appeared on day 62. Anti-biotherapy was adjusted to tigecycline combined with liposomal amphotericin B (L-AmB). At midnight, the abdominal pain worsened, and acute diffuse peritonitis was considered. CT showed some free abdominal gas under the diaphragm, and peritoneal fluid was detected (Fig. 3) . Emergency surgical management, including partial resection of the jejunum and ileum, was performed. There were 9 perforations in the jejunum 190-210 cm from the curved ligament, with an aperture of approximately 1-2 cm, and a perforated ileum was detected approximately 25 cm from the ileocecal part.

Histopathology of specimens from the jejunum and ileum showed broad septate fungal hyphae (Fig. 4) . Cultures of specimens from the jejunum also showed features such as Mucorales, and C. bertholletiae (accession no. MW915438) was identified according to the same protocols mentioned above. Antifungal susceptibility tests according to the Clinical and Laboratory Standards Institute (CLSI) M38-A2 broth microdilution document [16] were implemented. The susceptibility profiles of C. bertholletiae isolated from BALF and tissue showed fluconazole 256 μg/ml, itraconazole 0.5 μg/ml, posaconazole 0.5 μg/ml, voriconazole 8 μg/ml, AmB 2 μg/ml, and flucytosine 64 μg/ml. The susceptibility profiles of A. flavus isolated from BALF showed itraconazole 1 μg/ml, posaconazole 0.5 μg/ml, voriconazole 0.25 μg/ ml, and AmB 2 μg/ml. L-AmB was added to 1.0 mg/kg/day for 1 week, followed by fever resolution. She was covered pre-and postsurgery with L-AmB for 8 weeks. Considering the relief of symptoms and regression of lesions on imagery, our strategy switched to oral posaconazole 0.8 g/day. The patient was discharged in good condition for continuous therapy with oral posaconazole 0.8 g/day for almost 6 months. Due to the COVID-19 pandemic and other reasons, the patient's family finally gave up and the patient passed away at home last year. Mucormycosis and aspergillosis are opportunistic fungal infections that can lead to life-threatening complications and occur most commonly in individuals with neutropenia and prolonged immunosuppressive therapy [17] . An epidemiological article of 929 cases of mucormycosis found a correlation between the patient survival and the species within the Mucorales, given the conclusion of Cunninghamella spp. causing the highest percentage of crude mortalities and being an independent risk factor for death in the multivariate analysis [18] . As the most representative etiologic agent, C. bertholletiae occurs less frequently but causes refractory and fatal infections. A review of 15 cases of mucormycosis caused by Cunninghamella spp. indicated a patient population mainly consisting of neutropenia and transplantation [19] . GIM is the rarest type of Mucorales infection, and the successful management of the aggressive illness requires early surgical debridement, control of underlying disease, and suitable antifungal therapy [20] . A typical characteristic of pathophysiology of Mucorales infection is angioinvasion with thrombosis and thus necrosis of an affected part of the intestine. This will produce acute abdominal pain, possible bleeding, or perforation [20, 21] . To the best of our knowledge, this is the first report of pulmonary coinfection with C. bertholletiae and A. flavus with disseminated mucormycosis involving the jejunum caused by C. bertholletiae in a B-ALL patient in China.

Cunninghamella bertholletiae demonstrated to be the most resistant species among zygomycetes. Literature on C. bertholletiae indicates higher minimum inhibitory concentrations (MICs); 37% of the isolates had MICs of 2 μg/ml for AmB, while approximately 75% of the isolates appeared to be susceptible to posaconazole [22] . The high MICs to AMB and the low MICs for itraconazole and posaconazole against C. bertholletiae have been reported [22] [23] [24] [25] . In general, our results agree with other studies [22] [23] [24] [25] . Although decreased susceptibility to amphotericin B in vitro, the lipid formulations of AMB may achieve higher concentrations in vivo [22] . According to the epidemiologic cutoff values (ECVs) of antifungals for A. flavus [26] , the strain isolated from BALF could be considered a wild-type. Early diagnosis of mucormycosis is the key to treatment and prognosis. And the definitive diagnosis of mucormycosis depends on a combination of histopathological findings and standard mycological methods, as well as DNA sequencing of the ITS region, which has been suggested as a valuable target for identification at the genus and the species level by the CLSI guidelines [27] . Successful management of mucormycosis is on the basis of a multimodal manner, including reversal or revocation of underlying predisposing factors, early administration of suitable antifungal agents, and thorough resection of all infected tissues [28, 29] . According to the guidelines of European Conference on Infections in Leukaemia (ECIL-6) and European Confederation of Medical Mycology-The European Society for Clinical Microbiology and Infectious Diseases (ECMM-ESCMID), d-AmB and L-AmB are recommended as the first-line antifungal agent approved for the therapy of invasive mucormycosis [30] . High-dose L-AmB (10 mg/kg/day) immediately administered upon suspicion of mucormycosis greatly suppressed the infection in its early stage [31] . However, in the absence of surgical debridement for infected tissue, antifungal therapy alone is rarely curative [4] .

Our aim in this report is to highlight the need for a high clinical suspicion for Mucorales infection in neutropenic, immunocompromised, and diabetic patients. Direct microscopic testing with calcofluor white is the key to rapid diagnosis. In addition, effective multidepartmental communication with consulting physicians, such as hematologists, pulmonologists, and microbiologists, as well as immediate initiation of treatment, including surgical resection, can lead to improved patient outcomes in managing this rare but devastating disease and lay a solid foundation for the subsequent treatment of original disease.

Population based analysis of invasive fungal infections, france

Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries

The mucormycete-host interface

Host-iron assimilation: pathogenesis and novel therapies of mucormycosis

Epidemiology and clinical manifestations of mucormycosis

Invasive mold infections following combat-related injuries

Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between

A global analysis of mucormycosis in France: the RetroZygo study

Mucormycosis in haematological patients: case report and results of prospective study in Saint Petersburg

Clinical analysis of diabetic combined pulmonary mucormycosis

Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis

Hospital days, hospitalization costs, and inpatient mortality among patients with mucormycosis: a retrospective analysis of US hospital discharge data

We are what we eat!" Invasive intestinal mucormycosis: a case report and review of literature

Gastrointestinal mucormycosis in immunocompromised hosts

Pathogenesis of mucormycosis

Reference method for broth dilution antifungal susceptibility testing of filamentous fungi

Combined orofacial aspergillosis and mucormycosis: fatal complication of a recurrent paediatric glioma-case report and review of literature

Epidemiology and outcome of zygomycosis: a review of 929 reported cases

Increased virulence of Cunninghamella bertholletiae in experimental pulmonary mucormycosis: correlation with circulating molecular biomarkers, sporangiospore germination and hyphal metabolism

Gastrointestinal mucormycosis: a success story and appraisal of concepts

Gastrointestinal mucormycosis of the jejunum in an immunocompetent patient

In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents

Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers

In vitro and In vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella

Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales

Performance standards for antifungal susceptibility testing of filamentous fungi

Molecular tools for identification of zygomycetes and the diagnosis of zygomycosis

ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients

Challenges in the diagnosis and treatment of mucormycosis

Successful treatment of pulmonary mucormycosis caused by Cunninghamella bertholletiae with high-dose liposomal amphotericin B (10 mg/kg/day) followed by a lobectomy in cord blood transplant recipients